Half-Year Statement of IPSEN Liquidity Agreement with NATIXIS ODDO BHF

Rhea-AI Summary

IPSEN SA has reported updates related to its liquidity agreement with NATIXIS ODDO BHF as of June 30, 2022. The dedicated liquidity account includes 27,006 shares and €2,035,791.62. Previously, 12,751 shares and €3,137,934.80 were allocated. From January 1 to June 30, 2022, there were 1,568 purchase and 1,233 sell transactions, with volumes of 185,471 shares (€17.7M) purchased and 192,518 shares (€18.3M) sold. IPSEN, a biopharmaceutical company, generated €2.6 billion in Specialty Care sales in FY 2021 and operates globally.

Positive

• Increased liquidity resources, now totaling €2,035,791.62 in the account.
• High Specialty Care sales of €2.6 billion reported for FY 2021.

Negative

• Overall net sell transactions slightly exceed buy transactions within the reported period.
• A decrease in assets allocated to liquidity compared to the initial funding.

BOULOGNE-BILLANCOURT, France--(BUSINESS WIRE)-- Regulatory News:

Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of June 30, 2022, the following resources were included to the dedicated liquidity account:

• 27,006 shares
• €2,035,791.62

It is reminded that as of the date of the signature of the agreement, the following assets were allocated to the liquidity account:

• 12,751 shares
• €3,137,934.80

Between January 1^st, 2022 and June 30, 2022 have been executed:

• 1,568 purchase transactions
• 1,233 sell transactions

Under the same period, the volumes traded represented:

• 185,471 shares and €17,698,711.67 to the purchase
• 192,518 shares and €18,301,101.56 to the sell

Ipsen

Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With Specialty Care sales of €2.6bn in FY 2021, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen, excluding its Consumer HealthCare business, has around 4,500 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220706005622/en/

Investors

Craig Marks

Vice President, Investor Relations

+44 7584 349 193

Adrien Dupin de Saint-Cyr

Investor Relations Manager

+33 6 64 26 17 49

Media

Gwenan White

Executive Vice President, Communications and Public Affairs

+44 7876 391 429

Ioana Piscociu

Global Communications Director

+33 6 69 09 12 96

 

Source: IPSEN

FAQ

What is the liquidity agreement update for IPSEN (IPSEY) as of June 30, 2022?

As of June 30, 2022, IPSEN has 27,006 shares and €2,035,791.62 in its liquidity account under the agreement with NATIXIS ODDO BHF.

What were the trading volumes for IPSEN (IPSEY) from January to June 2022?

Between January 1 and June 30, 2022, IPSEN executed 1,568 purchase transactions and 1,233 sell transactions, totaling 185,471 shares purchased and 192,518 shares sold.

How much did IPSEN (IPSEY) generate in Specialty Care sales for FY 2021?

IPSEN generated €2.6 billion in Specialty Care sales for the fiscal year 2021.